Merck Research Laboratories
Department of Epidemiology
PO Box 1000, UG1D-60
North Wales,
PA
USA
19454-1099
Email:
christopher_mast@merck.com
Biographical Sketch:
Dr. T. Christopher Mast is an Associate Director in the Epidemiology Department of Merck Research Laboratories. He received his M.Sc. in Health Policy from the Harvard School of Public Health and his PhD in the Vaccine Sciences Division from the Johns Hopkins Bloomberg School of Public Health in Baltimore MD.
Prior to joining Merck Research Laboratories in 2000, Dr. Mast has worked on field projects in Uganda, Vietnam and Thailand. Since joining Merck, he has supported vaccine and drug development programs for rotavirus, HPV and HIV disease areas by designing and conducting international and domestic studies on disease burden, patient-reported outcomes and large-scale pharmacoepidemiological studies.
Relevant recent publications
Mast TC, DeMuro-Mercon C, Floyd LE, and Walters E. Impact of rotavirus gastroenteritis on the family. BMC Pediatrics 2009; 9:11.
Loughlin J, Wang FT, El Khoury A, Doherty M, Mast TC, Seeger JD. Adherence to the Recommended
Pentavalent Rotavirus Vaccine Administration Schedule in the United States: 2006-2007. Pediatr Infect Dis J. 2009 Jul;28(7):667-668. [Letter]
Wang F, Mast TC, Glass RJ, Loughlin J, Seeger J. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States: a claims-based analysis. Pediatrics, in press.
Chow CM, Choi K, Nelson EA, Chan PKS, Mast TC, DiStefano D, Tam JS, Bresee JS. Use of intravenous fluids in Hong Kong children hospitalised for diarrhoea and relationship to severity and aetiology. Vaccine 2009; (27S):F55–F60.
Mast TC, Walter E, Bulotsky M, Khawaja SS, Distefano DJ, Straus WL, Staat, MA. Burden of childhood rotavirus disease on health systems in the united states: results from active surveillance before rotavirus vaccine introduction. Pediatric Infectious Disease Journal, in press.